Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
World J Urol. 2023 Apr;41(4):909-919. doi: 10.1007/s00345-022-04116-x. Epub 2022 Aug 13.
To assess the prognostic value of sex for non-muscle-invasive/muscle-invasive bladder urothelial carcinoma (NMIBC/MIBC) treated with radical surgery.
The PubMed, Web of Science, and Scopus databases were searched in November 2021 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they involved the comparison of the overall, cancer-specific, progression, and recurrence-free survival of patients with NMIBC/MIBC. Formal sex-stratified meta-analyses of these outcomes were performed.
Thirty-one studies, which included 32,525 patients with NMIBC, and 63 studies, which included 85,132 patients with MIBC, were eligible for review and meta-analysis. Female sex was associated with worse cancer-specific survival (pooled hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.11-1.31) and overall survival (pooled HR, 1.02; 95% CI, 1.00-1.05) in patients with MIBC. In contrast, however, sex was not associated with cancer-specific survival (pooled HR, 1.01; 95% CI, 0.70-1.46), progression-free survival (pooled HR, 1.04; 95% CI, 0.88-1.24), and recurrence-free survival (pooled HR, 1.06; 95% CI, 0.98-1.16) in patients with NMIBC.
Sex is associated with an increased risk of worse survival outcomes in patients with MIBC but not in those with NMIBC. Given the genetic and social differences between sexes, sex may represent a key factor in the clinical decision-making process.
评估根治性手术治疗非肌层浸润性/肌层浸润性膀胱尿路上皮癌(NMIBC/MIBC)患者的性别预后价值。
根据系统评价和荟萃分析的首选报告项目声明,于 2021 年 11 月检索 PubMed、Web of Science 和 Scopus 数据库。如果研究比较了 NMIBC/MIBC 患者的总体、癌症特异性、进展和无复发生存率,则认为其符合纳入标准。对这些结局进行了正式的性别分层荟萃分析。
有 31 项研究(包括 32525 例 NMIBC 患者)和 63 项研究(包括 85132 例 MIBC 患者)符合审查和荟萃分析的条件。女性与 MIBC 患者的癌症特异性生存(合并危险比 [HR],1.21;95%置信区间 [CI],1.11-1.31)和总体生存(合并 HR,1.02;95% CI,1.00-1.05)较差相关。然而,在 NMIBC 患者中,性别与癌症特异性生存(合并 HR,1.01;95% CI,0.70-1.46)、无进展生存(合并 HR,1.04;95% CI,0.88-1.24)和无复发生存(合并 HR,1.06;95% CI,0.98-1.16)无关。
性别与 MIBC 患者生存结局较差的风险增加相关,但与 NMIBC 患者无关。鉴于性别之间存在遗传和社会差异,性别可能是临床决策过程中的一个关键因素。